Literature DB >> 27562298

Variations in supportive care needs of patients after diagnosis of localised cutaneous melanoma: a 2-year follow-up study.

Vanessa L Beesley1, B Mark Smithers2, Peter O'Rourke3, Monika Janda4, Kiarash Khosrotehrani5,6, Adèle C Green3,7.   

Abstract

PURPOSE: We aimed to describe variations in unmet supportive care needs of patients diagnosed with localised melanoma at high risk of recurrence and factors associated with initial and persisting moderate-to-high needs.
METHODS: We ascertained 386 patients diagnosed with clinical stage IB-II melanoma and administered surveys every 6 months for 2 years. The proportion experiencing at least one moderate-to-high need was assessed among salient subgroups: 306 patients with no previous melanoma and 80 with previous melanoma at enrolment, 30 who experienced disease recurrence during follow-up and 31 who developed another primary. Baseline factors associated with (a) needs at enrolment and (b) persistent needs over 2 years (or as long as disease-free) were identified by logistic regression analyses.
RESULTS: The proportion of patients with needs substantially declined over the first 6 months (if no previous melanoma, from 48 to 22 %, p < 0.001; previous melanoma, 35 to 17 %, p = 0.007), and in those remaining disease-free, needs declined further by 24 months (to 14 and 6 % respectively). By contrast, 50 % of those experiencing recurrence, and 39 % of those who developed another primary, reported needs. Stressful life events and anxiety were associated with needs at enrolment. At least one need, mainly fear of recurrence, persisted in 22 % of disease-free participants. Persistent needs were predicted by age, depression, anxiety and other stressful life events.
CONCLUSIONS: Melanoma patients' needs peak when first diagnosed and if disease recurs. Younger people or those experiencing additional stressful events, anxiety or depression are more likely to experience persistent needs and may benefit from tailored support.

Entities:  

Keywords:  Anxiety; Depression; Localised melanoma; Longitudinal study; Supportive care needs

Mesh:

Year:  2016        PMID: 27562298     DOI: 10.1007/s00520-016-3378-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  26 in total

1.  Emotional distress: the sixth vital sign--future directions in cancer care.

Authors:  Barry D Bultz; Linda E Carlson
Journal:  Psychooncology       Date:  2006-02       Impact factor: 3.894

2.  The unmet supportive care needs of patients with cancer. Supportive Care Review Group.

Authors:  R Sanson-Fisher; A Girgis; A Boyes; B Bonevski; L Burton; P Cook
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

3.  Does fear of cancer recurrence differ between cancer types? A study from the population-based PROFILES registry.

Authors:  Marieke van de Wal; Lonneke van de Poll-Franse; Judith Prins; Marieke Gielissen
Journal:  Psychooncology       Date:  2015-10-14       Impact factor: 3.894

4.  Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs.

Authors:  Vanessa L Beesley; Melanie A Price; Penelope M Webb; Peter O'Rourke; Louise Marquart; Phyllis N Butow
Journal:  Psychooncology       Date:  2012-08-31       Impact factor: 3.894

5.  Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia.

Authors:  Vanessa L Beesley; B Mark Smithers; Kiarash Khosrotehrani; Mohsina Khatun; Peter O'Rourke; Maria Celia B Hughes; Maryrose K Malt; Mark J Zonta; Gerard J Bayley; Andrew P Barbour; Lee J Brown; Justin D'Arcy; Christopher P Allan; Adèle C Green
Journal:  Psychooncology       Date:  2014-10-29       Impact factor: 3.894

6.  Patients' supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey.

Authors:  Jo Armes; Maggie Crowe; Lynne Colbourne; Helen Morgan; Trevor Murrells; Catherine Oakley; Nigel Palmer; Emma Ream; Annie Young; Alison Richardson
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

7.  Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015.

Authors:  M Arnold; C Holterhues; L M Hollestein; J W W Coebergh; T Nijsten; E Pukkala; B Holleczek; L Tryggvadóttir; H Comber; M J Bento; Ch S Diba; R Micallef; M Primic-Žakelj; M I Izarzugaza; J Perucha; R Marcos-Gragera; J Galceran; E Ardanaz; R Schaffar; A Pring; E de Vries
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-08-21       Impact factor: 6.166

8.  Supportive care needs of Canadian melanoma patients and survivors.

Authors:  Samuel P Hetz; Jennifer R Tomasone
Journal:  Can Oncol Nurs J       Date:  2012

9.  Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma.

Authors:  Zoe Stamataki; L Brunton; P Lorigan; A C Green; J Newton-Bishop; A Molassiotis
Journal:  Support Care Cancer       Date:  2014-09-05       Impact factor: 3.603

10.  The experience of melanoma follow-up care: an online survey of patients in australia.

Authors:  Janine Mitchell; Peta Callaghan; Jackie Street; Susan Neuhaus; Taryn Bessen
Journal:  J Skin Cancer       Date:  2014-11-19
View more
  2 in total

1.  The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers.

Authors:  Devesh Oberoi; Victoria M White; John F Seymour; H Miles Prince; Simon Harrison; Michael Jefford; Ingrid Winship; David Hill; Damien Bolton; Anne Kay; Jeremy Millar; Nicole Wong Doo; Graham Giles
Journal:  Support Care Cancer       Date:  2017-06-30       Impact factor: 3.603

2.  Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.

Authors:  Tavis Read; Scott Webber; Janine Thomas; Michael Wagels; Helmut Schaider; H Peter Soyer; B Mark Smithers
Journal:  BMJ Open       Date:  2017-10-06       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.